11:45 AM EDT, 07/22/2025 (MT Newswires) -- Klotho Neurosciences ( KLTO ) said Tuesday it is collaborating with AAVnerGene on adeno-associated virus manufacturing and targeted tissue delivery for its therapies to treat Alzheimer's, Parkinson's, ALS, and other conditions.

The collaboration will concentrate on producing KLTO-101 for Alzheimer's and Parkinson's diseases, KLTO-202 for ALS and other motor neuron disorders, and KLTO-303 for aging-related conditions, the company said.

"The two platform technologies offered by AAVnerGene will catapult our product candidates into the clinic at a faster pace, at a lower cost, a higher efficacy and purity compared to the current state-of-the-art AAV manufacturing processes," said Klotho CEO Joseph Sinkule.

Financial terms of the collaboration were not disclosed.

Price: 1.19, Change: -0.01, Percent Change: -0.83